The MIT Center for Collective Intelligence and MilliporeSigma brought together the thought-power of gurus in science, healthcare, public policy and other sectors to answer the question: how do we apply what we have learned from the COVID-19 pandemic for the future?
Researchers globally produce hundreds of thousands of studies annually. It can be difficult to know if at some time in the future they will be the foundation for a disease cure or a technology such as CRISPR that revolutionizes medicine. But many are exciting for what they point to or how they spike the imagination. BioSpace reviews 10 of the more compelling research stories of 2021.
To fast-track the time to market and gain a competitive edge, pharmaceutical development companies are increasingly implementing single-use technologies (SUT).
The United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna Covid-19 vaccines, top U.S. infectious disease official Anthony Fauci told the Washington Post newspaper.
Clarivate Plc released the company’s list of Highly Cited Researchers 2020 that identifies researchers who “demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.”
To quell concerns over the politicization of a potential vaccine for the novel coronavirus, nine pharmaceutical companies developing a preventative treatment signed a pledge promising to uphold the integrity of the scientific process ahead of any potential approval of a medication.
Blue Knight, a program created in partnership with Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA), chose seven startups from J&J’s global JLABS incubator network to participate in the fight against the world’s current Covid-19 pandemic and future ones.
Dr. Reddy’s Laboratories’ Foram Vaishnav discusses the role and impact of pharmacovigilance in the pharmaceutical industry.
Two Americans and a Briton won the 2018 Nobel Prize for Chemistry for harnessing the power of evolution to generate novel proteins.
Johnson & Johnson vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company’s products gave them ovarian cancer by arguing the plaintiffs’ science was flawed and the case should not have been heard in Missouri.